Available Vaccines
Mumps
Introduction
Mumps is a mild childhood infection most commonly affecting children aged 5 to 9 years. It is caused by the mumps virus and is transmitted from person to person through direct contact or respiratory droplets. Individuals with mumps are contagious from 2 days before to 9 days after the onset of parotid swelling. The illness typically begins with fever, malaise, headache, and the characteristic parotid gland swelling.
While mumps is often uncomplicated in children, adults are at higher risk of complications including meningitis, orchitis, and hearing loss. Orchitis occurs in approximately 20% of post-pubertal males with mumps, and both testes are affected in about 20% of these cases; however, mumps orchitis rarely results in permanent infertility. Acquisition of mumps during the first 12 weeks of pregnancy is associated with a 25% risk of spontaneous abortions, but fetal malformations following maternal mumps infection have not been reported.
Table 16.1 Vaccines Registered in Malaysia

Table 16.2 High-risk Group in Malaysia

Implication for Healthcare Workers (HCWs)
All healthcare workers (HCWs) and staff with regular patient contact should be immune to mumps, as transmission in healthcare settings endangers both HCWs and patients. Those without a history of mumps infection or prior vaccination should receive two doses of a mumps-containing vaccine, administered at least four weeks apart.
Evidence of Safety & Effectiveness
The mumps component of the MMR vaccine is moderately effective in preventing mumps infection. Two doses provide about 86% effectiveness, with a reported range of 32% to 95%, while one dose offers approximately 72% effectiveness, ranging from 49% to 91%. Despite this variability, receiving two doses remains the most effective strategy for reducing the risk of mumps and its complications. Serological studies of vaccinated children demonstrated that mumps virus-neutralizing antibody titres persist for at least a decade post-vaccination.
References
- Centers for Disease Control and Prevention. (2024, September 20). Mumps vaccine recommendations. U.S. Department of Health & Human Services. https://www.cdc.gov/mumps/hcp/vaccine-considerations/index.html
- Centers for Disease Control and Prevention. (n.d.). Adult immunization schedule notes [Web page]. U.S. Department of Health & Human Services. Retrieved September 30, 2025, from https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-notes.html#note-mmr
- Marin, M., Marlow, M., Moore, K. L., & Patel, M. (2018, January 5). Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus–containing vaccine in persons at increased risk for mumps during an outbreak. Morbidity and Mortality Weekly Report, 67(1), 33–38. https://doi.org/10.15585/mmwr.mm6701a7
- National Pharmaceutical Regulatory Agency (NPRA) Sistem Pendaftaran Produk & Perlesenan. https://quest3plus.bpfk.gov.my/pmo2/index.php
- World Health Organization. (2024, March 15). Mumps virus vaccines: WHO position paper, WER No. 11, 99, 115–133. Weekly Epidemiological Record. World Health Organization. https://iris.who.int/bitstream/handle/10665/376287/WER9911-115-133.pdf?sequence=1